ArticleOpen medicine (Warsaw, Poland)2026
Fast track hip and knee arthroplasty: impact of different hospital care levels.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Total knee and hip replacements are among the most common surgical procedures. Optimization of the treatment process is of great relevance and requires verification of effectiveness in different settings. The PROMISE study was carried out to achieve this. Methods: An optimized treatment process was implemented in 3 German hospitals with different levels of care. A total of 1,887 patients were included. The WOMAC Score was established as the outcome parameter at 3, 6 and 12 months after surgery. A mixed model for repeated measurements was used to estimate site-specific effects as well as the limits of the corresponding confidence intervals. To demonstrate homogeneous results across all sites, these outcomes needed to fall within a range defined by the overall effect ± the minimally clinically important difference (MCID), using a 95 % confidence interval. Results: All site-specific results ranged from (points [CI-limits]) -29.2 [-29.7; -28.7] to -24.4 [-24.5; -24.3] and were therefore within the range defined by the overall treatment effect and the MCID (25.4 ± 10). Conclusions: We could demonstrate homogeneous site-specific effects of the optimized process in the three most different settings of the German healthcare system. Therefore, an essential prerequisite for a system-wide rollout has been met.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.